{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/headache-cluster/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"603364e1-1e74-5796-9f29-7f6f277d42f3","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field a168d4af-d448-4509-bc53-4b1c3dbf0b8f --><h2>Changes</h2><!-- end field a168d4af-d448-4509-bc53-4b1c3dbf0b8f -->","summary":null,"htmlStringContent":"<!-- begin item 878d1f2f-74fe-4f80-b01e-e00b0fb4c5df --><!-- begin field 878f1471-ca38-4ed3-8a75-09b78650c7b4 --><p><strong>November 2017</strong> — reviewed. A literature search was conducted in August 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><!-- end field 878f1471-ca38-4ed3-8a75-09b78650c7b4 --><!-- end item 878d1f2f-74fe-4f80-b01e-e00b0fb4c5df -->","topic":{"id":"d4372db3-c286-5b08-ae88-4b378cc26f85","topicId":"1780a283-d8d8-4a78-9869-4aa0bcb926e5","topicName":"Headache - cluster","slug":"headache-cluster","lastRevised":"Last revised in November 2017","chapters":[{"id":"dded59b4-b26d-58ac-b4b5-22a36bbce96f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fb41d21e-afee-5c8f-9fe3-7e5d7273f990","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f42da194-bfee-5d0c-9cd9-fe2352e484d8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"603364e1-1e74-5796-9f29-7f6f277d42f3","slug":"changes","fullItemName":"Changes"},{"id":"49b37f22-5d81-55cd-9f09-2c42bfe7a440","slug":"update","fullItemName":"Update"}]},{"id":"fb7884e6-910a-5be8-b49b-4d0d9901e5bb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e4d8ae70-7df4-595f-b078-15b0686480bc","slug":"goals","fullItemName":"Goals"},{"id":"e06fcd82-7749-5fc4-99a5-a659ad138d75","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b2ce29d8-0327-5dc3-b537-4eb0d84ff0df","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"911f8cac-31a2-54f6-8084-565c4516e965","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"45526ba7-7e5c-5e4d-aea2-c6c4785109c9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"204fce42-b598-5c01-b2f8-dc34334f94ef","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d652875d-acbb-5f7e-9327-464a8d24509d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2513432e-c9c8-5a4a-b045-88b3c9db1c5f","slug":"definition","fullItemName":"Definition"},{"id":"f6b0ddc0-0058-5caa-a90e-fde4e7016138","slug":"cause","fullItemName":"Cause"},{"id":"24bb1ef8-f348-5f38-9375-b0ffcc04fe19","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad96cb6b-adfd-5eef-ac92-e130eebc9a8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"09b005ad-76ed-5ffb-9cf8-f7f5fdc3d524","slug":"complications","fullItemName":"Complications"}]},{"id":"eb2c501e-d43f-5455-b294-8c75e0b43b4f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"99fb5731-772f-5d15-92ac-3e0d36235be9","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"dd1bbca4-1759-5853-a0b4-d6c95f1b4e22","slug":"assessment","fullItemName":"Assessment"},{"id":"270554de-33be-56a1-9ab5-db4bc1d5bfeb","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4952c884-725e-51f7-bde4-95e2418f6d18","fullItemName":"Management","slug":"management","subChapters":[{"id":"d58dee4b-524d-5c05-ab56-a3f2e8267015","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5dbc1f0e-638e-542a-bfb4-76477f824f0b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bbfa7c46-4e1f-5d21-a8cb-de6d17b9dd04","slug":"sumatriptan-zolmitriptan","fullItemName":"Sumatriptan and zolmitriptan"}]},{"id":"49f18d8e-055b-5a9d-8737-d359c87ff9ae","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ae4fda2b-dde5-5641-aa58-5c38a3417e57","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1278ee56-1831-5a74-b634-e5de752cb567","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"11a5b228-ed75-5a88-aaef-1055082e8cfe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"88f71638-0d83-5cc8-9189-6a8cb83aede0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"04c06162-a368-59ad-b092-c583527f05a3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e2804080-7722-535f-84d1-3394e9874c9a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8b309d7e-58c0-5822-90e8-eb5941b856db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f42da194-bfee-5d0c-9cd9-fe2352e484d8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"18032e35-9441-540b-bdbc-7b6dcc3c0e57","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 0ea5ccf3-b0ab-4d97-af7b-7a7fffa5a176 --><h3>Previous changes</h3><!-- end field 0ea5ccf3-b0ab-4d97-af7b-7a7fffa5a176 -->","summary":null,"htmlStringContent":"<!-- begin item f876ffbd-e6ae-4187-be7c-28a5825768be --><!-- begin field 26f14092-d82b-443d-b387-7b6bfe364e7f --><p><strong>December 2016</strong> — minor update. The contraindications and interactions for verapamil have been updated in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>November 2012</strong> — reviewed. A literature search was conducted in October 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The topic has been restructured and more information added about primary and secondary headaches. Information from the guideline Headache: Diagnosis and management of headache in young people and adults commissioned by the National Institute for Health and Care Excellence (NICE) has been added. Minor changes have been made to the recommendations.</p><p><strong>March 2010</strong> — minor update. Advice from the NICE guideline Depression in adults with a chronic physical health problem regarding drug interactions between antidepressants and triptans has been added. Issued in April 2010.</p><p><strong>March to August 2009</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Together with the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/headache-assessment/\">Headache - assessment</a>, <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/headache-tension-type/\">Headache - tension-type</a>, this CKS topic replaces the former topic on Headache. Treatment of acute attacks with 100% oxygen is now recommended in addition to treatments previously recommended in the CKS guidance.</p><p><strong>September 2008</strong> — minor correction to the <em>Changes</em> section. Issued in September 2008.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>July 2005</strong> — update to text discussing nonsteroidal anti-inflammatory drugs (NSAIDs) in the Medicines management and Prescribing points sections. Issued in July 2005.</p><p><strong>January 2005</strong> — rewritten. Validated in March 2005 and issued in April 2005.</p><p><strong>December 2001</strong> — reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>October 2000</strong> — updated to incorporate the Department of Health Referral Guidelines for Suspected Brain Tumour and Suspected Children's Cancer.</p><p><strong>October 1998</strong> — written.</p><!-- end field 26f14092-d82b-443d-b387-7b6bfe364e7f --><!-- end item f876ffbd-e6ae-4187-be7c-28a5825768be -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}